21 Hrs
Source:
المشهد العربي
Novo Nordisk explores acquisitions to strengthen weight loss drug position
Novo Nordisk is studying acquisition strategies to strengthen its portfolio in weight-loss medications and to compete more effectively, especially with the impending loss of patent protection for Wegovy. This move comes amid a roughly 8% decline in the company's shares and expectations that its exclusive rights to the drug may lapse in the early 2030s, threatening its market position against competitors like Eli Lilly.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)